PMID: 15239391Jul 9, 2004Paper

Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease

International Journal of Hematology
Chikashi Yoshida, Junia V Melo

Abstract

Chronic myeloid leukemia (CML) is a stem cell disorder caused by a constitutively activated tyrosine kinase, the Bcr-Abl oncoprotein. An inhibitor of this tyrosine kinase, imatinib mesylate, is rapidly becoming the first-line therapy for CML. However, the development of resistance to this drug is a frequent setback, particularly in patients in advanced phases of the disease. Several mechanisms of resistance have been described, the most frequent of which are amplification and/or mutations of the BCR-ABL gene. To overcome resistance, several approaches have been studied in vitro and in vivo. They include dose escalation of imatinib, combination of imatinib with chemotherapeutic drugs, alternative Bcr-Abl inhibitors, inhibitors of kinases downstream of Bcr-Abl, farnesyl and geranylgeranyl transferase inhibitors, histone deacetylase, proteasome and cyclin-dependent kinase inhibitors, arsenic trioxide, hypomethylating agents, troxacitabine, targeting Bcr-Abl messenger RNA, and immunomodulatory strategies. It is important to understand that these approaches differ in efficiency, which is often dependent on the mechanisms of resistance. Further investigations into the molecular mechanisms of disease and how to specifically target the...Continue Reading

References

Sep 22, 1988·The New England Journal of Medicine·G CarulliF Ambrogi
Nov 1, 1994·Experimental Cell Research·N SakaiN Kuzumaki
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·T SkorskiB Calabretta
Aug 1, 1996·British Journal of Cancer·E S NewlandsM H Brampton
Dec 6, 1996·Science·R W KingM W Kirschner
May 9, 1998·Genes & Development·J Y ReutherA S Baldwin
Jun 24, 1998·Proceedings of the National Academy of Sciences of the United States of America·S TaageperaT J Hope
Oct 31, 1998·Current Opinion in Immunology·T S Griffith, D H Lynch
Jul 22, 1999·Blood Reviews·P J Vossebeld, P Sonneveld
May 29, 2000·Journal of Cellular Physiology·W D Cress, E Seto
Aug 3, 2000·Journal of the National Cancer Institute·P A MarksR A Rifkind
Aug 22, 2000·Nature·T TanabeS Asano
Aug 24, 2000·Proceedings of the National Academy of Sciences of the United States of America·V M RichonP A Marks
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Sep 22, 2001·Science·C BartheJ R Mahon
Feb 14, 2002·British Journal of Haematology·Stephen B MarleyMyrtle Y Gordon

❮ Previous
Next ❯

Citations

Apr 18, 2006·Current Treatment Options in Oncology·Merat Karbasian EsfahaniPeter H Wiernik
Jun 28, 2005·Proceedings of the National Academy of Sciences of the United States of America·Natalia L Komarova, Dominik Wodarz
Apr 28, 2007·The Cancer Journal·Janice M Mehnert, Wm Kevin Kelly
Oct 4, 2007·PloS One·Natalia L Komarova, Dominik Wodarz
Sep 3, 2010·PloS One·Allen A Katouli, Natalia L Komarova
Jun 15, 2005·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Zhuo ZhangHui Wang
Jun 7, 2005·Expert Opinion on Therapeutic Targets·Ladislav Novotny, Thomas Szekeres
Nov 26, 2005·Expert Opinion on Investigational Drugs·Paul A Marks, Milos Dokmanovic
Oct 5, 2007·Theoretical Population Biology·Natalia L Komarova, Dominik Wodarz
Dec 14, 2005·Current Opinion in Genetics & Development·Thomas O'HareBrian J Druker
May 11, 2005·Expert Opinion on Investigational Drugs·Peter M Fischer, Athos Gianella-Borradori
Sep 13, 2005·Seminars in Cancer Biology·Dominik Wodarz, Natalia L Komarova
Jan 24, 2008·The Annals of Pharmacotherapy·Helen M Marshall, Julia M Hammond
Dec 6, 2006·The Tohoku Journal of Experimental Medicine·Izumi IshikawaTakeshi Sasaki
Aug 10, 2005·Journal of Cellular Biochemistry·Milos Dokmanovic, Paul A Marks
Jun 16, 2007·The Journal of Pharmacology and Experimental Therapeutics·Sang Min LeeSun Hee Kim
Nov 25, 2004·Hematology·Stephen O'BrienPeter Valent
Dec 1, 2007·The Journal of Biological Chemistry·Jessica K AltmanLeonidas C Platanias
May 22, 2009·Cancer Research·Natalia L Komarova, Dominik Wodarz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.